 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- || Ceraxa (nanoliposomal ceramide) / Keystone Nano
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Metastases: Ceramide NanoLiposome in Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 29, 2024
P1, N=14, Completed, Sponsor: Keystone Nano, Inc
Unknown status --> Completed | N=24 --> 14 | Trial completion date: Aug 2019 --> Nov 2023 | Trial primary completion date: Aug 2019 --> Aug 2023
- | Ceraxa (nanoliposomal ceramide) / Keystone Nano
Trial completion date: KNAN2001: Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 3, 2023
P1, N=18, Not yet recruiting, Sponsor: Keystone Nano, Inc
Unknown status --> Completed | N=24 --> 14 | Trial completion date: Aug 2019 --> Nov 2023 | Trial primary completion date: Aug 2019 --> Aug 2023 Trial completion date: Sep 2024 --> Dec 2024
- || Ceraxa (nanoliposomal ceramide) / Keystone Nano
P1 data, Journal, Metastases: A phase I study of the ceramide nanoliposome in patients with advanced solid tumors. (Pubmed Central) - Sep 22, 2023
P1
Trial completion date: Sep 2024 --> Dec 2024 CNL exhibited an encouraging safety profile and pharmacokinetic parameters, with some signals of efficacy including prolonged stable disease in 1 patient with
- | Ceraxa (nanoliposomal ceramide) / Keystone Nano
Trial completion date, Trial primary completion date: KNAN2001: Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 8, 2023
P1, N=18, Not yet recruiting, Sponsor: Keystone Nano, Inc
CNL exhibited an encouraging safety profile and pharmacokinetic parameters, with some signals of efficacy including prolonged stable disease in 1 patient with Trial completion date: Jun 2022 --> Sep 2024 | Trial primary completion date: Dec 2021 --> Jul 2024
- || Ceraxa (nanoliposomal ceramide) / Keystone Nano
New P1 trial: KNAN2001: Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 19, 2021
P1, N=18, Not yet recruiting, Sponsor: Keystone Nano, Inc
- || nanoliposomal ceramide (KN-001) / Keystone Nano
Agreed. Was fellow on KN-001! 😀 I meant that one already predicts absence of cell intrinsic synergy. And there is suggestion of "anti-purposing" with antibiotics and #ICI Environmental repurposing might be relevant. (Twitter) - Sep 4, 2020
- Keytruda (pembrolizumab) / Merck (MSD), Yervoy (ipilimumab) / Ono Pharma, BMS
Pan-tumor analysis of the association of cancer and immune biology-related gene expression signatures with response to pembrolizumab monotherapy (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_686;
These features (Angiogenesis, mMDSC and Stroma/EMT/TGFβ) have been previously hypothesized to represent immune-suppressive axes with potential negative impact on immunotherapy efficacy. Future evaluation of the association of these signatures with response and survival outcomes in other cancer types and in randomized settings will provide additional insight into their prognostic or predictive character.
- ||||| Keytruda (pembrolizumab) / Merck (MSD), nanoliposomal ceramide (KN-001) / Keystone Nano
Clinical, Heterogeneity: #ESMO19 Outcomes with pembro mono in patients with treated brain metastases from KN 001, -010, -024, -042 presenter by @AMansfieldMD. Some heterogeneity. Those with brain mets were younger, more nonsquamous, more EGFR, I suspect more other alterations too. #OncoAlert (Twitter) - Sep 30, 2019
- Keytruda (pembrolizumab) / Merck (MSD), Yervoy (ipilimumab) / Ono Pharma, BMS
Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP) (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_3048;
All but 3% were recurrence-free after a median 15.3 m of treatment, thus validating the discontinuation of anti-PD1 in complete responders. Clinical trial identification: CCTIRS, #15.640.
- || nanoliposomal ceramide (KN-001) / Keystone Nano
JCO paper on KN001 5-yr survival data.... https://t.co/weNhdnCYhc (Twitter) - Jun 18, 2019
- |||| Keytruda (pembrolizumab) / Merck (MSD), nanoliposomal ceramide (KN-001) / Keystone Nano
Clinical: Long term data from KN-001 Pembro in #NSCLC being presented today. Remarkable 5-year OS 23.2% for treatment-naive patients and 15.5% for previously treated patients. Humbled to see significant improvement #ASCO19 #LCSM #OncoAlert https://t.co/45DuFSHQj6 (Twitter) - Jun 2, 2019
- | Ceraxa (nanoliposomal ceramide) / Keystone Nano
Trial completion date, Trial primary completion date, Metastases: Ceramide NanoLiposome in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 27, 2019
P1, N=24, Recruiting, Sponsor: Keystone Nano, Inc
Clinical trial identification: CCTIRS, #15.640. Trial completion date: Mar 2019 --> Aug 2019 | Trial primary completion date: Mar 2019 --> Aug 2019
- Ceraxa (nanoliposomal ceramide) / Keystone Nano
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: Ceramide NanoLiposome in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 30, 2017
P1, N=24, Recruiting, Sponsor: Keystone Nano, Inc
Trial completion date: Mar 2019 --> Aug 2019 | Trial primary completion date: Mar 2019 --> Aug 2019 Not yet recruiting --> Recruiting | Initiation date: Sep 2016 --> Mar 2017 | Trial primary completion date: Sep 2018 --> Mar 2019
- Ceraxa (nanoliposomal ceramide) / Keystone Nano
New P1 trial, Metastases: Ceramide NanoLiposome in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jul 15, 2016
P1, N=24, Not yet recruiting, Sponsor: Keystone Nano, Inc